Michael A Rogawski

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi The neurobiology of antiepileptic drugs
    Michael A Rogawski
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Neurosci 5:553-64. 2004
  2. ncbi The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease
    Michael A Rogawski
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892 4457, USA
    CNS Drug Rev 9:275-308. 2003
  3. ncbi What is the rationale for new treatment strategies in Alzheimer's disease?
    Michael A Rogawski
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 49 Convent Drive, Bethesda, MD 20892, USA
    CNS Spectr 9:6-12. 2004
  4. ncbi The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions
    Michael A Rogawski
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 10:685-92. 2004
  5. ncbi GluR5 kainate receptors, seizures, and the amygdala
    Michael A Rogawski
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892 4475, USA
    Ann N Y Acad Sci 985:150-62. 2003
  6. ncbi Diverse mechanisms of antiepileptic drugs in the development pipeline
    Michael A Rogawski
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 35 Convent Drive MSC 3702, Bethesda, MD 20892 3702, United States
    Epilepsy Res 69:273-94. 2006
  7. ncbi Anticonvulsant and proconvulsant actions of 2-deoxy-D-glucose
    Maciej Gasior
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
    Epilepsia 51:1385-94. 2010
  8. ncbi Termination of epileptiform activity by cooling in rat hippocampal slice epilepsy models
    Gholam K Motamedi
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892-3702, USA
    Epilepsy Res 70:200-10. 2006
  9. ncbi Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice
    Rafal M Kaminski
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892-4457, U.S.A
    Epilepsia 45:864-7. 2004
  10. ncbi Efficacy of the ketogenic diet in the 6-Hz seizure test
    Adam L Hartman
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
    Epilepsia 49:334-9. 2008

Collaborators

Detail Information

Publications37

  1. ncbi The neurobiology of antiepileptic drugs
    Michael A Rogawski
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Neurosci 5:553-64. 2004
  2. ncbi The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease
    Michael A Rogawski
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892 4457, USA
    CNS Drug Rev 9:275-308. 2003
    ....
  3. ncbi What is the rationale for new treatment strategies in Alzheimer's disease?
    Michael A Rogawski
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 49 Convent Drive, Bethesda, MD 20892, USA
    CNS Spectr 9:6-12. 2004
    ..Memantine also has neuroprotective properties and can inhibit Abeta-induced neurodegeneration...
  4. ncbi The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions
    Michael A Rogawski
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 10:685-92. 2004
    ....
  5. ncbi GluR5 kainate receptors, seizures, and the amygdala
    Michael A Rogawski
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892 4475, USA
    Ann N Y Acad Sci 985:150-62. 2003
    ....
  6. ncbi Diverse mechanisms of antiepileptic drugs in the development pipeline
    Michael A Rogawski
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 35 Convent Drive MSC 3702, Bethesda, MD 20892 3702, United States
    Epilepsy Res 69:273-94. 2006
    ....
  7. ncbi Anticonvulsant and proconvulsant actions of 2-deoxy-D-glucose
    Maciej Gasior
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
    Epilepsia 51:1385-94. 2010
    ..For comparison, we studied 3-methyl-glucose (3-MG), which like 2-DG accumulates in cells and reduces glucose uptake, but does not inhibit glycolysis...
  8. ncbi Termination of epileptiform activity by cooling in rat hippocampal slice epilepsy models
    Gholam K Motamedi
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892-3702, USA
    Epilepsy Res 70:200-10. 2006
    ..Practical devices to inhibit seizure activity may only need to induce small temperature drops, if the cooling can be applied sufficiently rapidly...
  9. ncbi Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice
    Rafal M Kaminski
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892-4457, U.S.A
    Epilepsia 45:864-7. 2004
    ..The 6-Hz model may be a valuable tool in drug development for the identification of GABAergic AEDs...
  10. ncbi Efficacy of the ketogenic diet in the 6-Hz seizure test
    Adam L Hartman
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
    Epilepsia 49:334-9. 2008
    ....
  11. ncbi The anticonvulsant activity of acetone, the major ketone body in the ketogenic diet, is not dependent on its metabolites acetol, 1,2-propanediol, methylglyoxal, or pyruvic acid
    Maciej Gasior
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892 3702, USA
    Epilepsia 48:793-800. 2007
    ..The anticonvulsant mechanism of acetone is unknown, but it is metabolized to several bioactive substances that could play a role...
  12. ncbi Anticonvulsant activity of androsterone and etiocholanolone
    Rafal M Kaminski
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892-3702, USA
    Epilepsia 46:819-27. 2005
    ..CONCLUSIONS: 5alpha,3alpha-A and 5beta,3alpha-A have anticonvulsant properties. Although of low potency, the steroids are present in high abundance and could represent endogenous modulators of seizure susceptibility...
  13. ncbi Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons
    Divina S Gryder
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892 4457, USA
    J Neurosci 23:7069-74. 2003
    ..Moreover, these results support the concept that GluR5 kainate receptors represent a novel target for antiepileptic drug development...
  14. ncbi Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466
    Brita Fritsch
    Epilepsy Research Section, National Institute for Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
    Epilepsia 51:108-17. 2010
    ..We assessed the ability of the noncompetitive AMPA receptor antagonist GYKI 52466 to protect against kainic acid-induced status epilepticus in mice...
  15. ncbi Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons
    Maria F M Braga
    Department of Neurology, F Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    J Pharmacol Exp Ther 330:558-66. 2009
    ....
  16. ncbi Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist
    Rafal M Kaminski
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    Neuropharmacology 46:1097-104. 2004
    ..Together with our in vitro cellular electrophysiological results, the present observations strongly support a unique mechanism of action of topiramate, which involves GluR5 kainate receptors...
  17. ncbi Evidence for low GluR2 AMPA receptor subunit expression at synapses in the rat basolateral amygdala
    Divina S Gryder
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892 3702, USA
    J Neurochem 94:1728-38. 2005
    ..Many BLA synaptic AMPA receptors are likely to be calcium permeable and could play roles in synaptic plasticity, epileptogenesis and excitoxicity...
  18. ncbi 11β-Hydroxylase inhibitors protect against seizures in mice by increasing endogenous neurosteroid synthesis
    Rafal M Kaminski
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
    Neuropharmacology 61:133-7. 2011
    ..We conclude that inhibition of CYP11B1 causes delayed seizure protection due to slow build-up of neurosteroids. Early seizure protection is independent of neurosteroids...
  19. ncbi The pheromone androstenol (5 alpha-androst-16-en-3 alpha-ol) is a neurosteroid positive modulator of GABAA receptors
    Rafal M Kaminski
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    J Pharmacol Exp Ther 317:694-703. 2006
    ..GABA(A) receptors could represent a target for androstenol as a pheromone, for which it is well suited because of high volatility and lipophilicity, or as a conventional hormonal neurosteroid...
  20. ncbi Adult murine skeletal muscle contains cells that can differentiate into beating cardiomyocytes in vitro
    Steve O Winitsky
    Molecular Physiology Section, Laboratory of Molecular Cardiology, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA
    PLoS Biol 3:e87. 2005
    ..By 6 d they begin to differentiate without fusing to recipient cardiac cells. Three months later, the tagged cells are visible as striated heart muscle restricted to the region of the cardiac infarct...
  21. ncbi Prolonged attenuation of amygdala-kindled seizure measures in rats by convection-enhanced delivery of the N-type calcium channel antagonists omega-conotoxin GVIA and omega-conotoxin MVIIA
    Maciej Gasior
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
    J Pharmacol Exp Ther 323:458-68. 2007
    ....
  22. ncbi Neuroprotective and disease-modifying effects of the ketogenic diet
    Maciej Gasior
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892 3702, USA
    Behav Pharmacol 17:431-9. 2006
    ....
  23. ncbi Effects of neurosteroids on epileptiform activity induced by picrotoxin and 4-aminopyridine in the rat hippocampal slice
    Patricia Salazar
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 49 Convent Drive Room 5A75 MSC 4457, Bethesda, MD 20892-4457, USA
    Epilepsy Res 55:71-82. 2003
    ..PTX and 4-AP-induced bursting in the hippocampal slice are useful models for directly assessing neurosteroid effects on seizure susceptibility under conditions that eliminate the factor of brain bioavailability...
  24. ncbi Epileptiform activity extinguished by amygdala infusion of the neurotoxin ibotenate in a rat model of temporal lobe epilepsy
    John R Pace
    Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Neurosurg 97:450-4. 2002
    ..CONCLUSIONS: Lesioning of an epileptic focus by convective distribution of ibotenate can produce an enduring suppression of seizure activity, indicating a chemical neurosurgical approach for epilepsy therapy...
  25. ncbi Neurosteroids and infantile spasms: the deoxycorticosterone hypothesis
    Michael A Rogawski
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
    Int Rev Neurobiol 49:199-219. 2002
    ..In addition, it further confirms the utility of pharmacological enhancement of GABA-mediated inhibition in the control of infantile spasms...
  26. ncbi Stress-induced deoxycorticosterone-derived neurosteroids modulate GABA(A) receptor function and seizure susceptibility
    Doodipala S Reddy
    Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Neurosci 22:3795-805. 2002
    ....
  27. ncbi Molecular targets for antiepileptic drug development
    Brian S Meldrum
    Centre for Neuroscience, Division of Biomedical and Health Sciences, School of Medicine, Kings College, London, United Kingdom
    Neurotherapeutics 4:18-61. 2007
    ..The growing understanding of the pathophysiology of epilepsy and the structural and functional characterization of the molecular targets provide many opportunities to create improved epilepsy therapies...
  28. ncbi New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels
    Michael A Rogawski
    Department of Neurology, School of Medicine, University of California, Davis, 4860 Y Street, Suite 3700, Sacramento, CA 95817, USA
    Curr Neurol Neurosci Rep 8:345-52. 2008
    ..Functionally, all of the new targets modulate neurotransmitter output at synapses, focusing attention on presynaptic terminals as critical sites of action for AEDs...
  29. ncbi New strategies for the identification of drugs to prevent the development or progression of epilepsy
    Dieter Schmidt
    Epilepsy Research Group, Goethestr 5, Berlin, Germany
    Epilepsy Res 50:71-8. 2002
    ..Overall, it was felt that the current preclinical strategies for the discovery and development of new AEDs have to be redefined in order to identify agents that are clearly superior to current medications...
  30. ncbi Progesterone, neurosteroids, and the hormonal basis of catamenial epilepsy
    Michael A Rogawski
    Ann Neurol 53:288-91. 2003
  31. ncbi Cerebellar ataxia, seizures, premature death, and cardiac abnormalities in mice with targeted disruption of the Cacna2d2 gene
    Sergey V Ivanov
    Basic Research Program, Science Applications International Corporation Frederick, Inc, National Cancer Institute at Frederick, Frederick, Maryland, USA
    Am J Pathol 165:1007-18. 2004
    ....
  32. ncbi Common pathophysiologic mechanisms in migraine and epilepsy
    Michael A Rogawski
    Department of Neurology, University of California Davis School of Medicine, 4860 Y St, Ste 3700, Sacramento, CA 95817, USA
    Arch Neurol 65:709-14. 2008
    ..Greater understanding of the shared mechanisms of epilepsy and migraine can provide a basis for the development of improved treatment approaches that may be applicable to both conditions...
  33. ncbi The anticonvulsant activity of acetone does not depend upon its metabolites
    Maciej Gasior
    Epilepsia 49:936-7. 2008
  34. ncbi Molecular targets versus models for new antiepileptic drug discovery
    Michael A Rogawski
    Epilepsy Res 68:22-8. 2006
    ..In vitro testing is not likely to replace screening in animal models because in vitro systems cannot model the specific pharmacodynamic actions required for seizure protection, and do not assess bioavailability and brain accessibility...
  35. ncbi The neuropharmacology of the ketogenic diet
    Adam L Hartman
    John M Freeman Pediatric Epilepsy Center, Johns Hopkins Hospital, Baltimore, Maryland 21287, USA
    Pediatr Neurol 36:281-92. 2007
    ....
  36. ncbi Endogenous neurosteroids modulate epileptogenesis in a model of temporal lobe epilepsy
    Giuseppe Biagini
    Dipartimento di Scienze Biomediche, Universita di Modena e Reggio Emilia, Modena, Italy
    Exp Neurol 201:519-24. 2006
    ..The 5alpha-reductase inhibitor finasteride, which blocks neurosteroid synthesis, reduced the latent period, indicating that glia-derived neurosteroids may be antiepileptogenic...
  37. ncbi Astrocytes get in the act in epilepsy
    Michael A Rogawski
    Nat Med 11:919-20. 2005